These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 901736)

  • 21. Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.
    Jaillon P; Poirier JM; Lecocq B; Jarreau C; Pays M; Richard MO; Cheymol G
    Eur J Drug Metab Pharmacokinet; 1986; 11(3):233-8. PubMed ID: 3816879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic analysis of intravenously and orally administered quinidine in cows.
    McGuirk SM; Muir WW; Sams RA
    Am J Vet Res; 1981 Sep; 42(9):1482-7. PubMed ID: 7325456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of quinidine and three of its metabolites in man.
    Rakhit A; Holford NH; Guentert TW; Maloney K; Riegelman S
    J Pharmacokinet Biopharm; 1984 Feb; 12(1):1-21. PubMed ID: 6747817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absolute bioavailability of quinidine in two sustained release preparations.
    Amlie JP; Storstein L; Olsson B; Fremstad D; Jacobsen S
    Eur J Clin Pharmacol; 1979 Aug; 16(1):45-8. PubMed ID: 499299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid elimination of quinidine in pediatric patients.
    Szefler SJ; Pieroni DR; Gingell RL; Shen DD
    Pediatrics; 1982 Sep; 70(3):370-5. PubMed ID: 7110810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serious bioavailability problems with a generic prolonged-release quinidine gluconate product.
    Meyer MC; Straughn AB; Lieberman P; Jacob J
    J Clin Pharmacol; 1982; 22(2-3):131-4. PubMed ID: 7068936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum quinidine levels after administration of three different quinidine preparations.
    Henning R; Nyberg G
    Eur J Clin Pharmacol; 1973 Dec; 6(4):239-44. PubMed ID: 4591150
    [No Abstract]   [Full Text] [Related]  

  • 28. Absorption of quinidine and dihydroquinidine in humans.
    Hailey DM; Lea AR; Coles DM; Heaume PE; Smith WJ
    Eur J Clin Pharmacol; 1981; 21(3):195-9. PubMed ID: 7318878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Kinidin-Duetter and quinidine sulphate in the prevention of atrial fibrillation. A comparison].
    Bjerkelund C; Orning OM
    Nord Med; 1967 Mar; 77(13):405-7. PubMed ID: 6020765
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative quinidine plasma profiles at steady state of two controlled-release products and quinidine sulfate in solution.
    Wright GJ; Melikian AP; Pitts JE; Crowe JT; Morley EM
    Biopharm Drug Dispos; 1987; 8(2):159-72. PubMed ID: 3593896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Average steady-state plasma levels with slow release quinidine preparations].
    Normand JP; Roux A; Bardet J; Kahn JC; Maspoli JJ; Jarreau FX; Sansarricq M; Flouvat B; Bourdarias JP
    Arch Mal Coeur Vaiss; 1979 Sep; 72(9):1006-13. PubMed ID: 116611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absorption of quinidine from an enteric-coated preparation.
    Fremstad D; Nilsen OG; Amlie J; Storstein L; Olsson B; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):107-12. PubMed ID: 499306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship between quinidine plasma level and clinical effect for a new quinidine retard-formulation (author's transl)].
    Gaul G; Aldor E
    Arzneimittelforschung; 1981; 31(9):1486-8. PubMed ID: 7197961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers.
    Covinsky JO; Russo J; Kelly KL; Cashman J; Amick EN; Mason WD
    J Clin Pharmacol; 1979; 19(5-6):261-9. PubMed ID: 469022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relative bioavailability of various quinidine preparations in man after a single oral dose].
    Terhaag B; Gieszinger U
    Pharmazie; 1982 Dec; 37(12):848-50. PubMed ID: 7163373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers.
    Johnsson G; Jordö L; Lundborg P; Regårdh CG; Rönn O
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):292-7. PubMed ID: 7000717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained-release quinidine (Kinidin Durules) in maintaining sinus rhythm after electroversion of atrial dysrhythmias.
    Resnekov L; Gibson D; Waich S; Muir J; McDonald L
    Br Heart J; 1971 Mar; 33(2):220-5. PubMed ID: 5572656
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of quinidine Lipettes -- a sustained release preparation.
    Eriksson JE; Hanson A; Hörlin R; Johansson BW; Ohlsson O; Otto U; Syrén G
    Acta Med Scand; 1979; 205(1-2):53-9. PubMed ID: 367087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.
    Guentert TW; Holford NH; Coates PE; Upton RA; Riegelman S
    J Pharmacokinet Biopharm; 1979 Aug; 7(4):315-30. PubMed ID: 512840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.